A pragmatic adaptation of the RANO clinical risk score for IDH-Wildtype glioblastoma in the absence of MGMT promoter methylation testing

Future Oncology · Published 2026-08-04 · DOI 10.1080/14796694.2026.2713370

Free full text

Authors (13)

İmdat Eroğlu, Sıla Soylu Koçoğlu, Eron Merovci, Gözde Savaş, Fatih Gürler, Osman Sutcuoglu, Ugur Coskun, Aytug Uner, Murat Ucar, Burak Karaarslan, Ahmet Özet, Nuriye Özdemir, Ozan Yazıcı

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Eroğlu, İ., Koçoğlu, S., Merovci, E., et al. (2026). A pragmatic adaptation of the RANO clinical risk score for IDH-Wildtype glioblastoma in the absence of MGMT promoter methylation testing. Future Oncology. https://doi.org/10.1080/14796694.2026.2713370

Related articles

• Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study · Future Oncology · 2026 · Same journal
• Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences · Future Oncology · 2026 · Same journal
• Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice · Future Oncology · 2026 · Same journal
• Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary · Future Oncology · 2026 · Same journal
• Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience · Future Oncology · 2026 · Same journal
• IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma · Future Oncology · 2026 · Same journal
• Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia · Future Oncology · 2026 · Same journal
• Sacituzumab govitecan in colorectal cancer: clinical evidence and future directions · Future Oncology · 2026 · Same journal
• A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer · Future Oncology · 2026 · Same journal
• Treatment outcomes with palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer who also have cardiovascular diseases: a plain language summary · Future Oncology · 2026 · Same journal